Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

University of Minnesota announces clinical trial for opioid vaccine

Researchers at the university ultimately aim to develop vaccines for a range of opioids.

By Brian Buntz | September 7, 2021

Marco Pravetoni

Marco Pravetoni

The University of Minnesota Medical School has developed a therapeutic vaccine for opioid use disorder that is the subject of a new Phase 1 randomized placebo-controlled clinical trial.

The trial, which recently begun enrollment, will be conducted at the Columbia University Irving Medical Center in New York. Sandra Comer, a professor of neurobiology at the College of Physicians and Surgeons of Columbia University, will lead the research.

Researchers at the University of Minnesota developed the vaccine candidate to selectively inhibit the euphoric and toxic effects of oxycodone, the semi-synthetic opioid drug. The vaccine stimulates the production of antibodies to oxycodone, which eventually halt its entry to the brain.

Oxycodone brands include Oxycontin, Xtampza ER, Oxaydo and Roxicodone.

In the long run, the researchers aim to develop a range of opioid vaccines for commonly abused drugs such as heroin and fentanyl, and fentanyl analogs, such as carfentanil. Their work is currently focused on initial Phase I clinical testing with the ultimate goal of advancing these novel medications to FDA approval.

The National Institute on Drug Abuse of the National Institutes of Health is offering financial support for the Phase 1 trial.

Opioid vaccine

A researcher holds a vial of an investigational opioid vaccine.

Marco Pravetoni, an associate professor of pharmacology and medicine at the University of Minnesota, is leading the drug discovery research. Pravetoni has also worked to develop a number of vaccines and monoclonal antibodies to treat respiratory depression and bradycardia from oxycodone, fentanyl and heroin. His research is featured in the Journal of Pharmacology and Experimental Therapeutics and the Journal of Medicinal Chemistry.

When Pravetoni asked about his inspiration for the research, he pointed to the goal to develop “more treatment options for opioid use disorders and overdose.” Opioid vaccines “will have a beneficial impact on patients, their families and society on many levels,” Pravetoni said.

“In this study, my laboratory will conduct pharmacokinetic and immunological monitoring in blood samples from immunized volunteers to ensure that they are making antibodies to oxycodone and determine whether or not the antibodies are preventing the drug from reaching the brain,” Pravetoni said.

“Inspired by the development of COVID-19 vaccines, we hope that translation of opioid vaccines will have a positive public health impact by preventing future epidemics,” Pravetoni said.


Filed Under: clinical trials, Drug Discovery
Tagged With: Marco Pravetoni, Oxaydo, oxycodone, Oxycontin, Roxicodone, University of Minnesota Medical School, Xtampza ER
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
How biosimulation and virtual trials can bust through clinical trial roadblocks
Complexity’s counterpoint: Understanding protocol optimization 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE